Ä¢¹½ÊÓƵAPP

Stephen Berenson is a Managing Partner at Ä¢¹½ÊÓƵAPP and a member of the company's Resource Allocation Committee. Stephen is chairman of the boards of Flagship-founded companies Sail Biomedicines, Cellarity and Seres Therapeutics (NASDAQ: MCRB) and is on the board of directors at Inari.

Stephen joined Flagship in June of 2017 after a 33-year career as an investment banker at J.P. Morgan. During that time, he worked across all major geographies, product areas and industry groups, and helped build the bank’s M&A, equities and technology investment banking businesses. He was co-founder of J.P Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. During Stephen’s leadership of the Board Initiative, more than 1,000 independent directors of public companies attended at least one of J.P. Morgan’s board events to discuss, debate and share best practices on the key issues they faced in the fulfillment of their duties.

Stephen previously built and ran Flagship’s Capital Formation and Business Development teams, and he served on the boards of directors of Flagship-founded companies Moderna, where he helped guide the company’s growth from pre-IPO through the COVID-19 pandemic and into the post-pandemic period, CiBO Technologies, and Repertoire Immune Medicines.

Stephen graduated from MIT in 1982 with an S.B. in mathematics. He is a member of the Visiting Committee for MIT’s Department of Mathematics. He previously served on the board of trustees of Jacob’s Pillow and the Mahaiwe Performing Arts Center.